


Intrinsically accessible motions enable Optimal binding of substrate or drugs



Conformational flexibility +
sequence variability mediates
substrate selectivity

- Two conformations of P450-CYP2B4:
open (orange) with a large substrate (bifonazole, red), and
closed (light blue) with the smaller substrate
4-(4-chlorophenyl) imidazole (blue)

See...

Sequence evolution

an information-theoretic approach

Residue index

	<i>i</i>				<i>i</i> +5	<i>i</i> +7	<i>i</i> +9
	R				E	V	N
	E				K	V	N
	K				E	V	N
	R				D	V	S
	D				K	V	S
	D				K	V	S
	E				R	V	S

correlated mutations (between *i* and *i*+5)
 conserved (between *i*+5 and *i*+7)

Information entropy (Shannon, 1951)

$$S(i) = \sum_{x_i=1}^{20} P(x_i) \log \frac{1}{P(x_i)}$$

Mutual information (MI)

$$I(i, j) = \sum_{x_i=1}^{20} \sum_{y_j=1}^{20} P(x_i, y_j) \log \frac{P(x_i, y_j)}{P(x_i)P(y_j)}$$

for correlated mutations analysis (CMA)

Mutual Information

without the influence of phylogeny

MI_p - to eliminate random noise and phylogenetic components

$$MI_p(i, j) = I(i, j) - APC$$

APC = Average product correction


$$= [I(i, x) I(j, x)] / \langle I(i, j) \rangle$$

	R				E	V	N
	E				K	V	N
	K				E	V	N
	R				D	V	S
	D				K	V	S
	D				K	V	S
	E				R	V	S

where $I(i, x)$ is the mean mutual information of column $i = \sum_j I(i, j)$


HIV-1 protease correlated mutation analysis (CMA)

MSA of HIV-1 protease



```
FLKIIQLLDDYPKCF  
FLKIIQLLDDYPKCF  
FLKIIQLLNDYPKCF  
FIKVVELFDEFPKCF  
LEKATKLFTTYDKMI
```


MI matrix $\mathbf{I}_{ij} = I(i, j)$




residue index

Shi and Malik (2000)

spectral clustering



reordered residue index



Dr. Ying Liu

MDR mutations distinguished by CMA


MSA of HIV-1 protease

Stanford HIV Drug Resistance Database
<http://hivdb.stanford.edu/>


```

CTLVGTAIHEMMHALGFLHEQNREDRDDWVR
CDKFGIVVHELGHVVGFWHEHTRPDREDHVV
CFRFGTVIHEFIHALGFYHAQSAYTRDDYVL
NFTVGSLEIHEIGHAFGLIHEHQRPDRDDYVI
CLTYGTPIHELMHALGFFHEQNRHERDSYVR
CDKFGIVVHELGHVVGFWHEHTRPDREKHVV
CDKFGIVVHELGHVVGFWHEHTRPDREHVV
CAYFGTIVHEIGHAIGFHEQSRPDRDDYIN
CVYHGIIQHELSHALGFYHEHTRSDRNKYVR
CINSGTIIHEVLHALGVHHEQARADRDGYVT
    
```

untreated



mobility profile



```


CTLVGTAIHEMMHALGFLHEQNREDRDDWVR
CDKFGIVVHELGHVVGFWHEHTRPDREDHVV
CFRFGTVIHEFIHALGFYHAQSAYTRDDYVL
NFTVGSLEIHEIGHAFGLIHEHQRPDRDDYVI
CLTYGTPIHELMHALGFFHEQNRHERDSYVR
CDKFGIVVHELGHVVGFWHEHTRPDREKHVV
CDKFGIVVHELGHVVGFWHEHTRPDREHVV
CAYFGTIVHEIGHAIGFHEQSRPDRDDYIN
CVYHGIIQHELSHALGFYHEHTRSDRNKYVR
CINSGTIIHEVLHALGVHHEQARADRDGYVT
    
```

treated by at least one drug



Drug-resistant cluster

Phylogenetic cluster



Summary


- two groups of correlated mutation sites

functional aspects	Structural location	structural dynamics
phylogenetic	exposed	mobile
multi-drug resistant	dimerization interface	restrained


Questions:

- Are key mechanical sites (e.g. hinges) conserved?
- Is there any correlation between sequence variability and structural dynamics?
- How does the structure ensure substrate specificity *and* conformational adaptability?


A systematic study of a set of enzymes




Evol




Correlation between sequence entropy & conformational mobility




sequence entropy



structural dynamics




Mobility increases with sequence entropy





Hinge sites are evolutionarily conserved

despite their moderate-to-high exposure to environment





3

Amino acids involved in intermolecular recognition are distinguished by **their co-evolution propensities**



Amino acids involved in intermolecular recognition are distinguished by **their high global mobility**



Summary

Four types of functional sites

Functional site	Mobility in global modes	Sequence evolution	Dominant Feature
Chemical (catalytic, ligand binding)	Minimal	Conserved	high fidelity, precision
Core	Minimal	Conserved	high stability
Hinge sites	Minimal	Conserved	rotational flexibility
Substrate recognition (specific)	High	High co-evolution propensity	adaptability

Allosteric communication mechanisms explored by network models

- Diffusion of signal obeys a **Markov process**
- The structure is modeled as a network
- Network connectivity given by Γ

References

Laplacian based manifold methods (Belkin & Niyogi)

Chennubhotla & Bahar Mol Systems Biology (2006); PLoS Comp Bio (2007)

Markov Model of Network Communication

$\Gamma = D - A$ where A = connectivity/affinity matrix and D = diagonal matrix of degrees

A *discrete-time, discrete-state* Markov process is defined by setting the conditional probability of signal transduction from residue j to i as

$$m_{ij} = a_{ij} / d_j$$

The conditional probability matrix $\mathbf{M} = \{m_{ij}\}$, also called the Markov transition matrix, is


$$\mathbf{M} = \mathbf{A} \mathbf{D}^{-1}$$

\mathbf{M} completely defines the stochastics of information transfer over the network of residues.

Hitting time: a measure of communication efficiency between two endpoints

Based on all possible pathways

path	# of steps	Path Probability
$j \rightarrow i$	1	0.5
$j \rightarrow k \rightarrow j \rightarrow i$	3	0.5^2
$j \rightarrow k \rightarrow j \rightarrow k \rightarrow j \rightarrow i$	5	0.5^3



$$H(j, i) = 1 \times 0.5 + 3 \times 0.5^2 + \dots = \sum_{j=1}^{\infty} (2j - 1) \times 0.5^j = 3.$$

path	# of steps	Path Probability
$i \rightarrow j \rightarrow k$	2	0.5
$i \rightarrow j \rightarrow i \rightarrow j \rightarrow k$	4	0.5^2
$i \rightarrow j \rightarrow i \rightarrow j \rightarrow i \rightarrow j \rightarrow k$	6	0.5^3

$$H(k, i) = 2 \times 0.5 + 4 \times 0.5^2 + \dots = 2 \sum_{j=1}^{\infty} j \times 0.5^j = 4.$$

Fluctuations as determinant of communication


$$H(n, i) = 1 + \sum_{k=1}^{n-1} H(n, k) m_{ki}$$

$$H(j, i) = \sum_{k=1}^n [\Gamma_{ki}^{-1} - \Gamma_{ji}^{-1} - \Gamma_{kj}^{-1} + \Gamma_{jj}^{-1}] d_k$$

$$C(i, j) = [\Gamma_{ii}^{-1} + \Gamma_{jj}^{-1} - 2\Gamma_{ij}^{-1}] \sum_{k=1}^n d_k.$$



Commute distance $\sim \langle (\Delta R_{ij})^2 \rangle$

Communication times




Distribution of Commute Times for Phospholipase A2 (1bk9)

His48 ,Tyr52, Asp99 – catalytic residues




See also

Active sites are distinguished by effective communication properties



CONCLUSION




- Proteins are designed to favor functional changes in their structure. Pre-existing soft modes facilitate substrate binding.
- Collective mechanics/allosteric dynamics are mediated by conserved residues
- The intrinsic motions confer enhanced flexibility at substrate **recognition** sites
- Correlated mutations at recognition sites enable substrate specificity while conferring conformational adaptability
- Accurate modeling of protein dynamics is essential to assessing target druggability

Mechanics vs chemistry?

How does complexity scale with size of the system?

Increasing specificity/chemistry



Dominance of molecular machinery

DISCUSSION

- Different tools for different time/length windows: MD cannot explore long-time processes for multimeric systems; ANM does not incorporate detailed atomic forces
- Not all evolutionarily correlated sites refer to structural or dynamic correlations
- Accurate modeling of protein dynamics is essential to computer-aided drug discovery, but not sufficient for quantitative evaluation of binding affinity
- Druggability simulations identify druggable sites, but not the type of drugs that optimally bind those sites

Acknowledgment

Group members

- Elia Zomot
- Anindita Dutta
- **Ahmet Bakan**
- Ignacio General
- **Murat Can Cobanoglu**
- Tim Lezon
- Mary Cheng
- Filippo Pulara
- **Indira Shrivastava**
- Mert Gur
- Kaitlyn Hu

Former members

- Lee-Wei Yang
- **Eran Eyal**
- **Dror Tobi**
- Basak Isin
- AJ Rader
- Chakra Chennubhotla
- Enrique Marcus
- Zheng Yang
- Enrique Markus
- **Ying Liu**
- **Lin Liu**
- Lidio Meireles
- Divesh Bhatt

Collaborators

- Angela Gronenborn
- Lila Gierasch
- Benoit Roux
- Michael Tsang
- John Lazo
- Andreas Vogt
- Mike Widom
- Andrej Sali
- Klaus Schulten
- Susan Amara
- Pemra Doruker



Dr. Ahmet Bakan
Comp & Systems Biology
U of Pittsburgh



Dr. Tim Lezon
Comp & Systems Biol,
U of Pittsburgh




Anindita Dutta
CMU/Pitt PhD Program



Dr. Eran Eyal
Cancer Research Institute
Sheba Medical Center, Israel



Burak Erman
Koc University, Istanbul



Ali Rana Atilgan
Sabanci University, Istanbul



Turkan Haliloglu
Bogazici University, Istanbul